FDA drug approval pace slows in 2026 due to leadership vacuum

Clinical trial streamlining efforts and drug approval timelines will decelerate as Makary’s successor prioritizes stability over policy shifts. Investor uncertainty following Makary’s departure will reduce risk appetite for early-stage drug approvals.

Implied probability (Yes)

68%